Antibody data
- Antibody Data
- Antigen structure
- References [5]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- GTX70485 - Provider product page
- Provider
- GeneTex
- Proper citation
- GeneTex Cat#GTX70485, RRID:AB_374164
- Product name
- Ku80 antibody
- Antibody type
- Polyclonal
- Reactivity
- Human, Mouse
- Host
- Rabbit
- Storage
- Keep as concentrated solution. Store at 4°C short term. For extended storage aliquot and store at -20°C or below. Avoid freeze-thaw cycles.
Submitted references XRN2 Links Transcription Termination to DNA Damage and Replication Stress.
mTOR inhibition induces compensatory, therapeutically targetable MEK activation in renal cell carcinoma.
Identification of Ror2 as a hypoxia-inducible factor target in von Hippel-Lindau-associated renal cell carcinoma.
ATR and Chk1 suppress a caspase-3-dependent apoptotic response following DNA replication stress.
VHL type 2B mutations retain VBC complex form and function.
Morales JC, Richard P, Patidar PL, Motea EA, Dang TT, Manley JL, Boothman DA
PLoS genetics 2016 Jul;12(7):e1006107
PLoS genetics 2016 Jul;12(7):e1006107
mTOR inhibition induces compensatory, therapeutically targetable MEK activation in renal cell carcinoma.
Bailey ST, Zhou B, Damrauer JS, Krishnan B, Wilson HL, Smith AM, Li M, Yeh JJ, Kim WY
PloS one 2014;9(9):e104413
PloS one 2014;9(9):e104413
Identification of Ror2 as a hypoxia-inducible factor target in von Hippel-Lindau-associated renal cell carcinoma.
Wright TM, Rathmell WK
The Journal of biological chemistry 2010 Apr 23;285(17):12916-24
The Journal of biological chemistry 2010 Apr 23;285(17):12916-24
ATR and Chk1 suppress a caspase-3-dependent apoptotic response following DNA replication stress.
Myers K, Gagou ME, Zuazua-Villar P, Rodriguez R, Meuth M
PLoS genetics 2009 Jan;5(1):e1000324
PLoS genetics 2009 Jan;5(1):e1000324
VHL type 2B mutations retain VBC complex form and function.
Hacker KE, Lee CM, Rathmell WK
PloS one 2008;3(11):e3801
PloS one 2008;3(11):e3801
No comments: Submit comment
No validations: Submit validation data